Anlongmed Fund is focused on early-stage investments in the life sciences and healthcare-related fields.
AnlongMed is a venture capital fund focuses on early stage life science and healthcare sectors. It is managed by a team led by Dr. Adam Zhao Chunlin, a veteran in life science with 30 years of experience, along with professionals with MNC, R&D, clinical, entrepreneurial and investment experience in both U.S. and China. The fund is anchored by Chinese Academy of Sciences. With extensive experience and connections from Chinese Academy of Sciences, Tsinghua University, Peking Union Medical College, and Bayhelix Group, AnlongMed strives to help entrepreneurs to start a venture in life science and healthcare in China. The fund has invested 22 firms from its first phase, including Netvation, a joint initiative toward new drug development between Chinese Academy of Science and Pfizer, Inc, 4 companies founded together with entrepreneurs across life science, biopharmaceutical, medical devices, and healthcare services.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jan 20, 2021
Skynor Medical
|
Series B | — | Health Care | — |
Jun 23, 2020
Sophonix
|
Series B | ¥100M | Biotechnology | — |
Aug 1, 2019
Zhenzhun Biotech
|
Series A | — | Biotechnology | Yes |
Jun 4, 2018
Laekna Therapeutics
|
Series A | $18.50M | Biotechnology | — |
May 8, 2018
Jun Hui Biotech
|
Seed | — | Health Care | Yes |
Anlongmed Fund has had 1 exits. Anlongmed Fund most notable exits include Connect Biopharmaceuticals
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Mar 18, 2021 | Connect Biopharmaceuticals | IPO | Biotechnology | Detail |